Topline data were announced from a phase 3 trial evaluating bemarituzumab plus chemotherapy in individuals with gastric or gastroesophageal junction cancer with FGFR2b overexpression.

FGFR2b overexpression was defined as 2+/3+ staining in ≥10% of tumor cells by ... plus chemotherapy were reduced visual acuity, punctate keratitis, anaemia, neutropenia, nausea, corneal epithelium ...